Last reviewed · How we verify

NCT03522792: NIRAH

Neurotensin - an Important Regulator of Appetite in Humans?

Status unknown NA Last updated 12 November 2019
What this trial tests

NA trial testing Neurotensin in Physiology - Regulation of Appetite and Food Intake in 18 participants. Status unknown.

Timeline
5 January 2018
Primary endpoint
1 May 2019
1 December 2019

Quick facts

Lead sponsorUniversity of Copenhagen
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingtriple
Primary purposebasic science
Enrollment18
Start date5 January 2018
Primary completion1 May 2019
Estimated completion1 December 2019
Sites1 location across Denmark

Drugs / interventions tested

Conditions studied

Sponsor

University of Copenhagen

Who can join

Adults 18 to 50, male only, with Physiology - Regulation of Appetite and Food Intake. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Neurotensin (NT) is a gut peptide released postprandially from the small intestine. It is known to exert a range of enterogastrone effects and in animal models it reduces food intake when administered by parenteral routes. This study investigates whether the anorexic effects of NT suggested by animal studies can be translated.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Neurotensin

Trials testing the same drug.

Other University of Copenhagen trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03522792.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing